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The binding of the VV oxidation products of two vanadi-
um(IV) compounds, [VO(dmpp)2] and [VO(maltolato)2],
which have shown promising anti-diabetic properties, to hu-
man serum albumin (HSA) in aqueous aerobic solution has
been studied by 1H saturation transfer difference (STD) NMR
spectroscopy and computational docking studies. Group epi-
tope mapping and docking simulations indicate a preference
of HSA binding to the 1:1 [VO2(dmpp)(OH)(H2O)]– and 1:2
[VO2(maltol)2]– vanadium(V) species. By using known HSA
binders, competition NMR experiments revealed that both
Introduction
Over the last few years vanadium compounds (VCs) have
attracted considerable interest from the scientific com-
munity due to their demonstrated pharmacological proper-
ties.[1] In particular, their potential use as oral insulin mi-
metic agents has been demonstrated by in vivo[2,3] and ex
vivo studies[4] as well as in clinical trials.[5] Their insulin-like
capacity to modulate several metabolic pathways may be
due to their inhibitory effect on protein tyrosine phosphat-
ases (PTPases) and/or the activation of tyrosine kinases,
which are responsible for the activation of signal transduc-
tion pathways, particularly in the insulin signalling cas-
cade.[6] Intensive research has been carried out to develop
VCs for use as orally administered drugs in the treatment
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complexes preferentially bind to drug site I. Docking simula-
tions carried out with HADDOCK together with restraints de-
rived from the STD results led to three-dimensional models
that are in agreement with the NMR spectroscopic data, pro-
viding useful information on molecular interaction modes.
These results indicate that the combination of STD NMR and
data-driven docking is a good tool for elucidating the interac-
tions in protein–vanadium compounds and thus for clarifying
the mechanism of drug delivery as vanadium compounds
have shown potential therapeutic properties.
of Type II diabetes mellitus (DM) at an effective non-toxic
dose. Among the many compounds synthesized to date,
only a few seem to show promise for this purpose. Bis-
(maltolato)oxovanadium(IV) (BMOV),[7] bis(picolinato)-
oxovanadium(IV) and bis(allixinato)oxovanadium(IV) as
well as other derivatives[8] have demonstrated anti-diabetic
properties[9–11] through indicators of insulin mimetism as-
sessed by in vitro and ex vivo studies such as glucose uptake
rates,[12,13] inhibition of free fatty acid (FFA) release[14] and
specific protein phosphorylation.[4,10] In vivo experiments
have confirmed their therapeutic activity and toxicity,[15,16]
established the minimum effective dose[17] and provided in-
formation about bioavailability and pharmacokinetics.
BMOV and similar compounds like bis(ethylmaltolato)-
oxovanadium(IV) (BEOV) have already been presented in
clinical trials.[18]
The vanadium complex bis(3-hydroxy-1,2-dimethyl-4-
pyridinonato)oxovanadium(IV), [VIVO(dmpp)2], has been
extensively studied. Its structure in the solid state has been
determined[19] and the different species formed in aqueous
solution under aerobic conditions were identified by using
different techniques and the respective formation constants
determined.[20] In vitro insulin mimetic and toxicity studies
with two cell lines, the mouse fibroblast SV 3T3 and the
human skin fibroblast F26,[21] have been conducted. Studies
with the human fibroblast cell line, 3T3-L1,[15] as well as
with human erythrocytes[22] have also been carried out to
test its cytotoxicity and glucose uptake enhancement ca-
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pacity. Recently, its anti-diabetic action was recognized
through an ex vivo study with isolated primary rat adipo-
cytes, which demonstrated that this compound improves
glucose internalization, inhibition of FFA release, and has
the capacity to activate the insulin signalling cascade
through phosphorylation of the key proteins of this path-
way.[23] In vivo studies with obese Zucker rats by using mag-
netic resonance techniques (MRI/MRS) confirmed the pos-
itive effects of [VIVO(dmpp)2] on glucose and lipid meta-
bolism, reinforcing its promising anti-diabetic capacity.[24]
However, the mechanism of the therapeutic action of
VCs in the human body has not yet been clarified. The in-
creased pharmacological effect of chelated VIV complexes
compared with VOSO4 has been attributed, in part, to in-
creased absorption in the gastrointestinal tract.[25] The dif-
ferences in biodistribution and efficacy observed between
non-chelated and chelated vanadyl ions result from a small
portion of the administered complex remaining intact after
absorption.[21,26] A major concern is how this intact frac-
tion of the VCs is transported in the blood stream and is
taken up by the cells of peripheral tissues.[27] Thus, it is
important to know the interactions between the adminis-
tered VCs and endogenous macromolecular components
and/or small bioligands (such as lactate and citrate) present
in blood serum to determine whether the decomposition of
the VCs occurs or ternary complexes are formed, and to
investigate the role of serum proteins in the transport of
VCs.[28–34] This information is crucial in the search for a
rational drug design to improve the therapeutic efficacy of
these compounds.
The two main serum proteins involved in the transport
of vanadium species (both VIV and VV) are human serum
transferrin (Tf) and albumin (HSA). The interaction of
vanadyl (VIV) and vanadate (VV) with transferrin has been
detected by different techniques, including gel electrophore-
sis, ultrafiltration, chromatographic techniques, atomic ab-
sorption spectrometry (AAS) and inductively coupled
plasma mass spectrometry (ICP-MS).[35,36] Structural infor-
mation on these interactions was obtained by spectroscopic
techniques, such as UV/Vis and FTIR and FT Raman spec-
troscopy.[37] Vanadate binds to the two FeIII binding sites
of apo-transferrin as the dioxidovanadium(V) cation, VO2+,
to form a (VO2+)2–Tf complex without the need of a syner-
gistic binding anion, as shown by 51V NMR spec-
troscopy,[38] whereas apo-transferrin requires such a syner-
gistic cation to bind two equivalents of the oxidovanadi-
um(IV) cation, VO2+, at these sites.[39] HSA strongly binds
one equivalent of VO2+ in the CuII site at the N terminus
and several equivalents, weakly and non-specifically, to
carboxylate side-chains of surface amino acids.[40] However,
when the VO2+/HSA ratio is 1:1 or lower, a binuclear metal
species, (VO2+)2–HSA, is formed.[29] EPR spectroscopy was
used as an essential tool of such extensive interaction stud-
ies of VO2+ with Tf and HSA.[28,29,41] It is not yet fully clear
in which form the VO2+ ion is transported to the target cells
in the organism as the higher concentration of HSA in the
blood could compensate its much lower affinity towards
VO2+ relative to transferrin.[42] In addition, the competition
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effects of small bioligands present in the serum also need
to be taken into consideration.[29]
The interaction of VIV compounds, including BMOV
and [VO(dmpp)2], with apo-Tf, HSA and small bioligands
present in blood serum has been studied by EPR and circu-
lar dichroism (CD).[27–34,43]The results indicate that, besides
the case in which the binding of the carrier ligand to vana-
dium is very weak, for example, 6-methylpicolinate, mixed
species are formed with transferrin with possible partial
carrier ligand displacement, to form cis-[VO(carrier)x(Tf)]
species (x = 1, 2; carrier ligand = picolinato, maltolato,
dmpp). In the case of HSA, mixed species cis-[VO(carrier)2-
(HSA)] involving hydrogen bonding and/or hydrophobic in-
teractions with the protein surface have also been proposed.
The formation of ternary species between the proteins
and the VO–carrier complex is an important issue as it af-
fects the distribution of species in the blood plasma. There-
fore independent evidence of their presence was an impor-
tant objective of this work. Although it is usually accepted
that the metal ion is transported in the blood in the VIV
oxidation state,[27,44] almost independently of the initial oxi-
dation state of the VC, oxidation may occur, resulting in the
formation of a limited amount of diamagnetic VV species,
which can be studied by NMR spectroscopy. In this work
we studied the interaction in aqueous solution of vanadate/
Hdmpp complexes with HSA by using the 1H saturation
transfer difference (STD) NMR technique.[45] This tech-
nique provides data on the interaction of small molecules
with a protein, validation of binding epitopes, estimation
of affinity constants and site-specific information through
competition studies. The vanadate/Hdmpp (M/L = 1:2)
solution contains both 1:1 and 1:2 VV species (Scheme 1),
the same species that result from the dissolution of the solid
[VIVO(dmpp)2] in water under aerobic conditions.[20]
Scheme 1. A) Chemical structures of 3-hydroxy-1,2-dimethyl-4-pyr-
idinone (1, Hdmpp), 3-hydroxy-2-methyl-4-pyrone (2, Maltol) and
bis(maltolato)oxovanadium(IV) (3, BMOV) (with K1 = 107.5 and
K2 = 106.2). B) Chemical equilibrium representing the dissolution
of the solid bis[3-hydroxy-1,2-dimethyl-4-pyridinonato]oxovanadi-
um(IV), [VIVO(dmpp)2] in H2O under physiological conditions and
the resulting oxidation products, the vanadium(V) species
[VVO2(dmpp)(H2O)(OH)]– and [VVO2(dmpp)2]–, with M/L ratios of
1:1 and 1:2, respectively (with K1 = 1010.48 and K2 = 105.25).
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The use of the diamagnetic vanadate/Hdmpp system in-
stead of an aerobic solution of [VIVO(dmpp)2] avoids the
presence of a small amount of paramagnetic species in solu-
tion resulting from incomplete oxidation,[20] which would
not allow the correct use of 1H STD NMR experiments.
Competitive 1H STD NMR experiments with two known
inhibitors of site I and site II of HSA, warfarin and ibup-
rofen, respectively (for a definition of site I and site II see
the Supporting Information), were performed to discrimi-
nate the preferential binding site of the VV coordinated spe-
cies and Hdmp.[46] A parallel study was also carried out
with the vanadate/maltol system to investigate the behav-
iour of the [VIVO(maltolato)2] compound (Scheme 1). The
STD results were complemented by data-driven docking
calculations performed with HADDOCK,[47,48] taking into
account the information from STD experiments, resulting
in 3D models that illustrate the interaction of VV species
with HSA, one of the main plasma proteins. Herein we
show that this procedure is a useful tool for providing im-
portant information on drug delivery, an approach not pre-
viously employed in the study of the use of vanadium com-
pounds as therapeutic drugs.
Results and Discussion
Figure 1 presents the 1D 1H NMR spectra of solutions
containing 5 mm free Hdmpp (A), vanadate/Hdmpp (1:2,
1 mm in vanadate) in the presence of 0.03 mm HSA (B) and
the 1H STD spectrum of solution B (C).
Spectrum A shows the signals corresponding to the two
methyl groups and the aromatic 5-H and 6-H protons, as-
signed in accordance with the literature.[20] In the spectra
of solutions containing 1:2 vanadate/dmpp, multiple signals
are observed for each type of proton, which have been as-
signed in the figure, indicating the presence in solution of
three main species in slow exchange on the NMR timescale:
Figure 1. 1H NMR spectra of A) an aqueous solution of 5 mm Hdmpp, B) an aqueous solution of vanadate/Hdmpp (1 mm in vanadate)
in an M/L ratio of 1:2 with 30 mm HSA at pH = 7 and C) STD NMR spectrum of solution (B). A spin-lock pulse of 30 ms was used to
remove protein resonances. The signal assignments are shown in the figure: L is the free Hdmpp and VL and VL2 are the 1:1
[VO2(dmpp)(H2O)(OH)]– and 1:2 [VO2(dmpp)2]– complexes, respectively. The difference in the vertical scale of the reference (A,B) and
STD (C) spectra is due to the different number of scans used in the respective acquisitions (see the Exp. Sect.).
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the free dmpp and two vanadium(V) complexes, the 1:1
[VO2(dmpp)(H2O)(OH)]– and 1:2 [VO2(dmpp)2]– VV species
(Scheme 1). When HSA was added to the vanadate/dmpp
system (spectrum B), the resonances of dmpp in all species
broaden and lose resolution, as expected, due to their inter-
action with the protein and the small increase in solution
viscosity. Only signals of the small molecules are observed
as the protein resonances were suppressed by using a spin-
lock filter during the acquisition.
A similar study was carried out with the vanadate/maltol
system and the 1H NMR signals of the obtained spectra
are assigned in Figure 2, in agreement with literature
data[49] and as confirmed by 1H NMR spectra obtained
from solutions of vanadate/maltol at different metal/ligand
(M/L) ratios (data not shown).
In the spectrum of vanadate/maltol, M/L = 1:2, two sig-
nals for the methyl group and the 5-H and 6-H aromatic
protons are observed corresponding to free maltol and the
1:2 VV complex, [VO2(maltolato)2]– (Scheme 1), in slow ex-
change on the NMR timescale.[49] Again for this system, all
the resonances broaden in the presence of HSA (Figure 2,
B), reflecting the binding of maltol and [VO2(maltolato)2]–
to the protein and the small increase in the viscosity of the
solution. The relative intensities of the resonances of the
species detected in solution for the two systems are in agree-
ment with the values of the formation constants determined
for the 1:1 and 1:2 complexes in both systems. Whereas in
the vanadate/Hdmpp system the association constants for
the 1:1 and 1:2 species are, respectively, K1 = 1010.48 m–1
and K2 = 105.25 m–1,[20] in the vanadate/maltol system the
corresponding association constants are K1 = 107.5 m–1 and
K2 = 106.2 m–1.[49]
Figure 1 (C) shows the 1H STD NMR spectrum of the
solution containing vanadate/dmpp (1:2) and HSA. The ap-
pearance of the resonances of the three species L, VL and
VL2 in the spectrum indicates, qualitatively, that all these
www.eurjic.org FULL PAPER
Figure 2. 1H NMR spectra of A) an aqueous solution of 60 mm maltol, B) an aqueous solution of vanadate/maltol (1 mm in vanadate)
in an M/L ratio of 1:2 with 30 mm HSA at pH = 7 and C) STD NMR spectrum of solution B. A spin-lock pulse of 30 ms was used to
remove protein resonances. The signal assignments are shown in the figure: L is the free maltol and VL and VL2 are the 1:1 [VO2(malto-
lato)(H2O)(OH)]– and 1:2 [VO2(maltolato)2]– complexes, respectively. The difference in the vertical scale of the reference (A,B) and STD
(C) spectra is due to the different number of scans used in the respective acquisitions (see Exp. Sect.).
species bind to the protein. However, only through an inte-
gration of the signals in spectra B and C and the determi-
nation of the corresponding ASTD values [by using Equa-
tions (1) and (2), see the Exp. Sect.] is it possible to draw
conclusions about the relative binding strengths of the dif-
ferent species to the protein and to identify the group epi-
tope for each one by group epitope mapping (GEM). The
ASTD values allowed full GEM characterization of the van-
adate/Hdmpp system (Table 1).
Table 1. Values of GEM relative to the highest values of ASTD (5-
H of the 1:1 species and 6-H of the 1:2 species for vanadate/Hdmpp
and vanadate/maltol systems, respectively) obtained from the inter-
action of all the small molecules with HSA.
GEM [%]
Small molecule 6-H 5-H CH3 N-CH3
Hdmpp 75 82 61 42
[VO2(dmpp)(H2O)(OH)]– 65 100 59 41
[VO2(dmpp)2]– 75 83 59 41
Maltol 79 93 65 –
[VO2(Maltol)2]– 100 97 30 –
In this case, although all the species seem to interact with
HSA, the values obtained indicate that there is a slight pref-
erence for the binding of the 1:1 species and through the 5-
H proton, as this resonance is the highest saturation-receiv-
ing proton. The calculated values of GEM for all the
Hdmpp protons were normalized relative to the value for
5-H. Similar studies carried out with the vanadate/maltol
system (1 mm in vanadate) with M/L = 1:2 in the presence
of HSA (0.03 mm) led to the 1H STD NMR spectrum
shown in Figure 2 (C) and the GEM values in Table 1. The
presence of all the resonances in the STD spectrum indi-
cates that both free maltol and the 1:2 species bind to the
protein. However, according to the GEM values, the strong-
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est interaction with HSA occurs through 6-H of the 1:2
species, although a rather similar saturation transfer is ob-
served for 5-H and 6-H.
To investigate the possible binding sites on HSA, com-
petitive 1H STD NMR studies with the most interactive
species were carried out in the presence of warfarin and
ibuprofen, two known binders to site I and site II of HSA,
respectively.[50] The displacement of binding species from
these sites by the corresponding reported specific inhibitor
after being added to the initial solution of vanadate systems
and HSA reflects a direct competition and interaction of
the species at these sites.[50]
Integration of the competitive 1H STD NMR spectra for
the vanadate/dmpp (1:1) and HSA solution (Figure 3) led
to the ASTD values presented in Table 2. It can be concluded
that the interaction of the 1:1 complex [VO2(dmpp)-
(H2O)(OH)]– with the binding site I is slightly favoured.
Although displacement of the species from both site I
and site II of HSA was observed, according to the ASTD
values, in the absence and presence of warfarin and ibup-
rofen, the largest decrease occurs in the presence of warfa-
rin for all the ligand protons of the 1:1 complex, which indi-
cates that binding to site I is favoured over site II. It is also
known that ibuprofen displaces species at site I of HSA,
albeit to a lesser extent, and so, if the interaction occurs
through site II a higher displacement would be expected
and reflected by a smaller ASTD value.
Similarly, Figure 4 presents typical spectra of the compe-
tition studies, through the 1H STD NMR technique, for the
vanadate/maltol (1:2) and HSA system in the presence and
absence of warfarin and ibuprofen, and the corresponding
ASTD values are presented in Table 2.
The results obtained for this system are in agreement
with those for the vanadate/Hdmpp system. The ASTD val-
ues in Table 2 show that, again in this system, greater dis-
placement occurs from site I, as revealed by the larger de-
www.eurjic.org FULL PAPER
Figure 3. 1H NMR spectra of A) a solution containing vanadate/Hdmpp (1:2.5, 1 mm in vanadate) and 0.03 mm HSA to which 0.1 mm
warfarin (structure i) has been added, B) the STD spectrum of the same solution as in A, C) a solution of vanadate/Hdmpp (1:2.5, 1 mm
in vanadate) and 0.03 mm HSA to which 0.4 mm ibuprofen (structure ii) has been added and D) the STD spectrum of the same solution
as in C. A selective saturation pulse (5 s) was applied to the 0 ppm region of the protein. A 30 ms spin-lock pulse was calibrated to avoid
unwanted protein resonances. In this study, a solution of vanadate/Hdmpp, 1 mm in vanadate and an M/L ratio of 1:2.5 was used to
allow the observation of the resonances assigned to the free ligand as well as those of the 1:1 and 1:2 species, and thus to identify the
behaviour of the three species relative to protein binding. Competitor resonances are indicated by * (warfarin) and # (ibuprofen). The
difference in the vertical scale of the reference (A,C) and STD (B,D) spectra is due to the different number of scans used in the respective
acquisitions (see the Exp. Sect.).
Table 2. Values of ASTD for all protons of the species [VO2(dmpp)(H2O)(OH)]– and [VO2(maltol)2]–, which preferentially bind to HSA,
after the addition of 0.4 mm ibuprofen or 0.1 mm warfarin to solutions containing the vanadate/Hdmpp,maltol systems and the protein.
The percentage of displacement is reflected by the decrease in the ASTD value upon the addition of the inhibitor.
ASTD Displacement by competition [%]
6-H 5-H CH3 N-CH3 6-H 5-H CH3 N-CH3
[VO2(dmpp)(H2O)(OH)]– 10.67 16.42 9.67 6.73
vs. Ibuprofen 2.41 2.18 2.36 2.44 77 87 76 64
vs. Warfarin 0.02 0.04 0.03 0.06 99 98 99 99
[VO2(maltolato)2]– 11.7 11.4 3.5 –
vs. Ibuprofen 6.1 5.8 2.6 – 48 49 26 –
vs. Warfarin 3.4 2.4 1.2 – 71 79 66 –
crease in the ASTD values for all the protons of the [VO2-
(maltolato)2]– complex in the presence of warfarin. Al-
though these results do not exclude the possibility of bind-
ing to any additional sites of the protein not screened in this
study,[50] a common behaviour towards the HSA binding of
these VV species with a similar chemical structure is demon-
strated, with a slight preference of this type of compound
for site I relative to site II.
To complement the STD NMR spectroscopic data with a
more detailed structural representation, molecular docking
studies were carried out between HSA and each of the VV
species (small molecules) by using HADDOCK.[47,48] Fig-
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ure 5 shows the 3D docking models for the binding of the
small molecules under study to HSA site I obtained from
HADDOCK calculations.
The results are in agreement with the NMR spectro-
scopic data, supporting the NMR observation of the pre-
dominant interactions of [VO2(dmpp)(H2O)(OH)]– and
[VO2(maltol)2]– complexes with HSA, as shown by the rela-
tively low HADDOCK score for these species. The protein
residues close to and interacting with the small molecules
remain conserved in all the calculations, which reflects the
consistency of the results. As shown in Figure 5, the aro-
matic moiety is in close proximity to the hydrophobic resi-
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Figure 4. 1H NMR spectra of A) a solution containing vanadate/maltol (1:2, 1 mm in vanadate) and 0.03 mm HSA to which 0.1 mm
warfarin (structure i)) has been added, B) the STD spectrum of the same solution as in A, C) a solution of vanadate/maltol (1:2, 1 mm
in vanadate) and 0.03 mm HSA to which 0.4 mm ibuprofen (structure ii) has been added and D) the STD spectrum of the same solution
as in C. A selective saturation pulse (5 s) was applied to the 0 ppm region of the protein. A 30 ms spin-lock pulse was calibrated to avoid
unwanted protein resonances. Competitor resonances are indicated by * (warfarin) and # (ibuprofen). The difference in the vertical scale
of the reference (A,C) and STD (B,D) spectra is due to the difference in the number of scans used in the respective acquisitions (see the
Exp. Sect.).
Figure 5. HADDOCK models for the interaction of HSA (warfarin
pocket, drug site I) with small molecules: A) the free ligand
Hdmpp, B) the free ligand maltol, C) [VVO2(dmpp)2]–, D) [VVO2-
(maltolato)2]– and E) [VVO2(dmpp)(OH)(H2O)]–. The main inter-
acting residues are shown by stick representation and electrostatic
and van der Waals interactions are represented by blue and pink
dashed lines, respectively. The figures were drawn with PyMOL.
dues (L238, F223, W214), namely L238, which is present in
all the modelled compounds. For the [VO2(dmpp)-
(H2O)(OH)]– species, the model shows a large number of
hydrophobic interactions with the planar ring, which con-
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tributes to its greater stability when compared with the
other species. The binding of the small molecules to the
protein is also stabilized by electrostatic interactions, mainly
with K199 and H242, but also with other positively charged
residues (K195, R222, R257). The binding site of the maltol
and dmpp VV complexes differs slightly. Although the R222
residue interacts directly with the VV species in the dmpp
complexes, in [VO2(maltol)2]– this residue is replaced by
R257, showing a different orientation of the small molecule,
which may be attributed to the higher bulk effect of the
aromatic moiety of dmp. The two larger VV complexes, with
an M/L ratio of 1:2, seem to displace a large number of
protein side-chains, establishing interactions with residues
lying deeper in the pocket (e.g., Y214). The [VO2(dmpp)2]–
species is found in the majority of the models in a very
different binding position, located at the surface of the pro-
tein. This is likely because the larger dmpp moiety cannot
be accommodated in the binding pocket without severe
steric hindrance from the protein side-chains, which may
explain the lower binding affinity. Even for the small set
of solutions (Table 3, small cluster of [VO2(dmpp)2]–) that
penetrate the pocket of HSA site I, there are no stabilizing
interactions between the protein and the second dmpp
moiety, which is in support of steric effects. For [VO2-
(maltolato)2]–, both maltolato moieties are stabilized by
hydrophobic interactions with residues Y214, F223, R222
and L238, as well as the above-mentioned electrostatic in-
teractions, conferring a higher affinity of this VV species on
the binding pocket compared with uncoordinated maltol.
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Table 3. Results of HADDOCK calculations from the top ranking clusters after water refinement for each compound in their interaction
with HSA. The HADDOCK score, energies of van der Waals and electrostatic interactions and buried surface area (BSA) were obtained
from the docking calculations automatic analysis.
Hdmpp [VO2(dmpp)(H2O)(OH)]– [VO2(dmpp)2]– Maltol [VO2(maltol)2]–
Cluster size 257 219 4 196 153 59
Haddock score [a.u.] 15.93.5 –8.81.8 12.011.9 23.83.7 24.90.4 2.61.8
van der Waals [kcal/mol] –11.12.9 –166.816.9 –104.12.8 –21.312.9 –19.44.3 –61.66.3
Electrostatic [kcal/mol] –19.30.8 –26.71.1 –30.52.0 –23.80.7 –15.61.2 –30.80.6
BSA [Å2] 324.727.7 496.314.9 736.320.6 461.29.1 295.816.9 711.86.7
Conclusions
The results presented in this work show that the species
that result from the dissolution and oxidation of [VIVO-
(dmpp)2], a vanadium compound that has demonstrated
promising anti-diabetic and anti-obesity ability, bind to
HSA, the most abundant protein in blood plasma. Similar
results were obtained with the species originating from the
dissolution and oxidation of the well-known [VIVO-
(maltolato)2] (BMOV) complex, which is already in clinical
trials. The 1H STD NMR technique has provided valuable
information concerning the binding of these VCs to HSA.
Competitive STD NMR experiments revealed that site I of
HSA is the main site involved in this binding. Thus, HSA
appears to be an important vehicle for the transport of va-
nadium species once in the blood stream and their delivery
to target cells. The molecular docking studies supported by
the NMR spectroscopic data indicate a preference for the
binding of 1:1 [VO(dmpp)(H2O)(OH)]– to HSA site I
relative to the 1:2 [VO2(dmpp)2]– complex, as shown
by the lower HADDOCK score. The binding of [VO2-
(maltolato)2]– to this site is also favoured over free maltol.
The 1H STD NMR technique has proven to be a useful
tool for studying the interactions of these VV complexes
with HSA. In addition, the docking simulations of these
interactions complement the STD NMR spectroscopic
data, allowing the interaction of metal-coordinated systems
with macromolecules to be modelled with high resolution,
an important issue in this field of research. Together, the
results presented in this work contribute to a better under-
standing of the fate of VCs and their derivatives after their
administration and once in the blood stream.
Experimental Section
Reagents and Solutions: Sodium metavanadate, NaVO3 (99.9%), 3-
hydroxy-1,2-dimethyl-4-pyridinone (Hdmpp), 3-hydroxy-2-methyl-
4-pyrone (maltol, 99%), human serum albumin (HSA), ibuprofen,
warfarin, D2O (99.6% D), DCl (wt. 35%, 99% D) and NaOD (wt.
30%, 99% D) were purchased from Sigma–Aldrich. All reagents
were used without further purification.
Stock solutions of HSA (1 mm), ibuprofen (2 mm), warfarin (2 mm),
vanadate (6 mm), Hdmpp (60 mm) and maltol (60 mm) were pre-
pared in D2O. Solutions containing vanadate and Hdmpp in M/L
ratios of 1:2, 1:2.5 and 1:5 were prepared by adding the appropriate
volumes of metal and ligand stock solutions. The vanadate/maltol
solutions in M/L ratios of 1:2, 1:5 and 1:20 were prepared similarly.
Samples containing HSA (30 μm) and vanadate/dmpp or vanadate/
maltolato (500 μm in vanadate), in different M/L ratios were ana-
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lysed by 1H NMR spectroscopy. In all cases a large excess of the
VV complex relative to the protein was used as required by the STD
protocol.
Competition studies were performed with warfarin and ibuprofen,
two known binders of site I and site II of HSA, respectively.[50]
Samples containing HSA (30 μm), vanadate/dmpp or vanadate/
maltolato solutions (500 μm in vanadate and in an M/L ratio of
1:2.5) and ibuprofen (400 μm) or warfarin (100 μm) were analysed.
The pH of all the solutions was adjusted to the physiological value
(pH 7–7.4) by using DCl or NaOD, and measured with a pH meter
equipped with a combined pH electrode Sentek P13/S7. The pH
values were not corrected for the isotopic effect.
1H NMR Spectroscopy: 1H NMR spectra were recorded with a
Varian VNMRS 600 NMR spectrometer operating at 599.72 MHz
by using a pulse field gradient (PFG) inverse 3 mm probe at 298 K.
The pulse sequence for the 1H NMR STD spectra acquisition[51]
used a double pulse field gradient spin echo (DPFGSE) to ef-
ficiently remove the water signal. The NMR spectrometer used ac-
quired the STD NMR spectra directly from phase cycling to calcu-
late the STD amplification factor and the 1D 1H NMR spectra
were used as off-resonance reference spectra. All the spectra were
acquired by using the following parameters: spectral width of
8 kHz, number of transients 128 for 1D 1H and 1024 for 1H STD
NMR spectra, acquisition time of 2 s and repetition time of 5 s. A
previously calibrated spin-lock filter (T1ρ) of 30 ms was used to
remove protein resonances. The difference in the number of tran-
sients used for the reference 1D and STD 1H NMR spectra was
corrected through normalization according to the Equation (1) in
which ISTD is the intensity of a signal in the STD NMR spectrum





The STD amplification factor (ASTD) was determined according to
Equation (2) in which the “small molecule (SM) excess” is the ratio
[SM]/[P], with [SM] as the total concentration of the VV coordi-
nated species and [P] is the total protein concentration.
ASTD = Rel. STD%SMexcess (2)
Group epitope mapping (GEM) values were obtained for each pro-
ton by normalizing the ASTD values of all protons of the SM to
the proton presenting the highest STD effect. All the spectra were
processed and analysed by using the Mestre Nova software.[58]
Protein–Small-Molecule Docking Studies: To provide a more de-
tailed insight into the binding mode, HADDOCK was used[47,48]
to derive a model of the interaction. The crystal structure of the
complex of HSA with warfarin (PDB ID: 2BXD)[52] was selected
as a representative structure for HSA because competition experi-
ments show a preferential interaction of the small molecules with
the warfarin binding site.
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The 3D structures of the small molecules, Hdmpp, maltol and their
respective VV-coordinated species, were generated by using a hybrid
parametrization scheme as the complexes contain an unusual vana-
dium metal atom and a high number of bonds (six) to this central
atom. To assign charges and geometric parameters for the aromatic
moieties, a semi-empirical quantum chemistry package (SQM, part
of the AmberTools package[53]) through the wrapper ACPYPE[54]
with default settings, except for the net charge that depends on
the binding molecule (neutral for Hdmpp and maltol, –1 for their
respective VV coordinated species). This software uses AM1-BCC
parameters, tuned to reproduce HF/6-31G* RESP charges for par-
tial charge calculations. The semi-empirical character of the calcu-
lations provides reasonable parametrization accuracy within a few
minutes.
The VVO2+ metal centre was manually parametrized by using the
geometrical features characterized by Caravan et al. for complexes
with maltol.[49] The 1:1 octahedral VV species coordinate two water
molecules, one of which is deprotonated at physiological pH and
was thus represented accordingly. To avoid artifacts due to the
highly charged vanadate ion, the total charge of the intervening
atoms was reduced while keeping the same ratio and net charge
(+1).
The docking was performed with HADDOCK version 2.2[47,48] by
using CNS1.3[55] for the structure calculations as this software al-
lows the integration of biochemical and/or biophysical information
to drive the modelling. The docking protocol consists of three
steps: 1) rigid body docking, 2) semi-flexible refinement by using a
simulated annealing protocol in torsion angle space and 3) final
refinement in explicit water. Non-bonding interactions were calcu-
lated with the OPLS force field[56] using a cut-off at 8.5 Å. The
electrostatic potential (Eelec) was calculated by means of a shift
function, and a switching function, between 6.5 and 8.5 Å, was
used for the van der Waals potential (Evdw). The HADDOCK score
was used to rank the generated models. It consists of a weighted
sum of intermolecular electrostatic, van der Waals, desolvation
(ΔGsolv)[57] and ambiguous interaction restraint (AIR) energies, de-
fined in Equation (3).
Haddock score = 0.2Eelec + 1.0Evdw + 1.0EΔGsolv + 0.1EAIR (3)
The ambiguous interaction restraints used to drive the docking
were defined as follows: 1) the small molecule was always treated
as an active residue, 2) for the 1:2 species, considering their sym-
metrical conformation, only one of the ligands was considered
active, 3) the residues of the HSA binding site were considered as
active only during the rigid-body docking stage whereas for the
remainder of the docking protocol they were defined as passive.
This effectively pulls the ligand molecule to the appropriate site of
the protein during rigid-body docking while allowing a more re-
laxed exploration of the binding pocket during the refinement
stage. The binding site of 2BXD is defined as the residues at around
5 Å from the warfarin molecule: 150, 195, 199, 211, 214, 215, 218,
219, 222, 238, 241, 242, 257, 260, 261, 264, 290, 291, 292. The GEM
data was incorporated as ambiguous distance restraints during the
semi-flexible and water refinement stages. The carbon atoms
bonded to the 5-H/6-H protons were required to be within 4 Å of
any residue in the binding pocket.
The docking was performed with default HADDOCK settings, ex-
cept for the following parameters: 1) the number of structures gen-
erated in the three stages of the docking protocol increased to 5000/
400/400, 2) all hydrogen atoms were kept, 3) the random exclusion
of a fraction of the AIRs was disabled, 4) the random exclusion of
a fraction of the AIRs was disabled, 5) the number of molecular
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dynamics steps for both rigid-body high-temperature torsion angle
dynamics (TAD) and the rigid-body cooling stage were set to zero
to avoid expulsion of the ligand from the pocket, 6) the initial tem-
perature for the second TAD cooling step was reduced to 500 K,
for the same reason as the previous and 7) the clustering cut-off
for the final solutions was reduced to 1 Å instead of the default
7.5 Å, as is adequate for a small ligand.
Supporting Information (see footnote on the first page of this arti-
cle): Details about the drug sites I and II of HSA mentioned in
this work, the warfarin and ibuprofen binding sites, respectively,
why they were chosen for this study, their localization in the protein
and structural features.
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